Psyence Biomedical Ltd. (PBMWW) income statement

PBMWWNasdaqPharmaceutical PreparationsFiscal year ends March 31Also trades as PBM

Financials through fiscal 2026, year ended Mar 31, 2026Last filing: 20-F on Jun 22, 2026Score 0/30

$0.01−0.00 (-2.50%)

Close on Oct 30, 2026Market cap –P/E –Yield –

Psyence Biomedical Ltd. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2026 2026-03-31	FY 2025 2025-03-31	FY 2024 2024-03-31	FY 2023 2023-03-31
Research & Development	1.47	0.34	0.95	1.61
Selling & Marketing	0.22	0.48	0.08	0.01
Interest Expense	0.01	0.01	0.05	–
Interest & Investment Income	–	–	0.00	0.00
Income from Equity Investments	-0.05	–	–	–
Pretax Income	-6.23	-3.66	-2.75	-3.23
Net Income incl. Noncontrolling Interests	-6.94	1.01	-51	-3.21
EPS (Basic)(per share)	-12.56	32.76	-29,214.06	-2,462.88
EPS (Diluted)(per share)	-12.56	32.76	-29,214.06	-2,462.88
Shares Outstanding (Basic, Weighted)(shares)	0.55	0.03	0.00	0.00
Shares Outstanding (Diluted, Weighted)(shares)	0.55	0.03	0.00	0.00

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Mar 31, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2026: –

Financial strength

Current ratio: –
Debt to equity: –
Debt to assets: –
Cash to current liabilities: –

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –